You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

News Room

Announcements

Date

Announcement

   

June 22, 2021

Repligen Corporation Announces Agreement to Acquire Polymem S.A. Read More

February 8, 2021

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

October 27, 2020

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More

October 1, 2020

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

June 29, 2020

Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More

April 26, 2019

Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies.  Read More

Septermber 4, 2018

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

June 28, 2018

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand.  Read More

June 27, 2018

Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands.  Read More

June 23, 2017

Repligen Corporation and Spectrum Inc. to Join Forces.  Read More

December 15, 2016

Repligen acquires TangenX Technology Corporation.  Read More

October 4, 2016

Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification.  Read More

April 4, 2016

Repligen acquires Atoll GmbH.  Read More

 

In the News

Date

Title

Publication

     

July 26, 2021

Repligen Corporation set to significantly expand bioprocessing manufacturing capactiy and create 130+ new jobs in Waterford

IDA Ireland

June 13, 2021

Repligen buys Frech filtraion firm Polymem Dan Stanton
BioProcess International

May 19, 2021

Coronavirus Spike Protein Captures Resin Available for Future Deployment GEN

February 12, 2021

New Affinity Resin for COVID-19 Vaccine Purification

GEN

February 10, 2021

Repligen and Navigo target next-wave COVID vaccines with affinity resin

Dan Stanton
BioProcess International
December 17, 2020

America's Best Mid-size Companies
Repligen: #15

Andrea Murphy, Hank Tucker
Forbes
November 19, 2020 Repligen CEO Tony Hunt Knows Why Success Takes Time Marilyn Munch
Investor's Business Daily
October 28, 2020 Repligen strengthens downstream offering with $200m ARTeSYN acquisition Dan Stanton
BioProcess International
October 8, 2020

Navigo and Repligen Team on COVID-19 Vaccine Affinity Resin

Dan Stanton
BioProcess International
September 1, 2020

Continuous Processing: A Step on the Way to Bioprocess 4.0

Gareth John Macdonald
GEN
July 1, 2020

Repligen boosting single-use portfolio with Engineered Molding Technology buy

BPI Staff
BioProcess International
February 24, 2020

Repligen up on OPUS® and Gene Therapy Demand

Dan Stanton
BioProcess International
October 1, 2019 Using Alternating Tangential Flow with Fed-Batch Cultures

GEN

August 12, 2019 Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application.

Samsung BioLogics’ cell culture technique to cut production life by 30%
 

Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application 

Samsung BioLogics implants cell-culturing tech
 
Samsung Biologics

Pulse News

Yahoo News

Korea Biomed
May 20, 2019 OPUS focus: Repligen expands to support chromatography demand Dan Stanton
BioProcess International

 


Press Contact

Sondra Newman
Senior Director, Investor Relations

press @ repligen.com

Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115

download repligen logo